SPINOGENIX

SPG302 is the first synaptic regenerative therapy to be tested in ALS, and Spinogenix is aiming to make it the first such therapy in Alzheimer's as well... SPINOGENIX is developing a new class of regenerative therapeutics to restore memory and motor functions lost in neurodegenerative and psychiatric diseases... Spinogenix has designed SPG302, a compound that acts in an entirely new manner to help restore the brain connections (synapses) lost in neurodegenerative disorders including Amyotrophic Lateral Sclerosis, Alzheimer's disease and many others.